Allena Pharmaceuticals, Inc. Net Income

Net Income of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Income growth rates and interactive chart. Net income (NI), also called net earnings, is calculated as sales minus cost of goods sold, selling, general and administrative expenses, operating expenses, depreciation, interest, taxes, and other expenses. It is the profit available to all shareholders, both preferred and common.


Highlights and Quick Summary

  • Net Income for the quarter ending March 31, 2022 was $-11.8 Million (a 13.99% increase compared to previous quarter)
  • Year-over-year quarterly Net Income decreased by -15.45%
  • Annual Net Income for 2021 was $-48.7 Million (a 48.16% increase from previous year)
  • Annual Net Income for 2020 was $-32.8 Million (a -30.62% decrease from previous year)
  • Annual Net Income for 2019 was $-47.3 Million (a 32.8% increase from previous year)
  • Twelve month Net Income ending March 31, 2022 was $-48.8 Million (a 0.36% increase compared to previous quarter)
  • Twelve month trailing Net Income increased by 11.27% year-over-year
Trailing Net Income for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-48.8 Million $-48.7 Million $-48.6 Million $-43.9 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Income of Allena Pharmaceuticals, Inc.

Most recent Net Incomeof ALNA including historical data for past 10 years.

Interactive Chart of Net Income of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Net Income for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-11.81
2021 $-10.36 $-12.69 $-13.97 $-11.64 $-48.66
2020 $-10.26 $-8.03 $-6.98 $-7.59 $-32.85
2019 $-11.36 $-13.29 $-11.27 $-11.42 $-47.34
2018 $-9.61 $-9.51 $-8.65 $-7.88 $-35.65
2017 $-6.68 $-4.67 $-4.63 $-5.67 $-21.65
2016 $-6.21 $-18.29 $-24.51
2015 $-14.24 $-14.25

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.